[Subscriber Special] Capricor Therapeutics (CAPR): The Illusion of a Pipeline
A clinical-stage biotech with no cash flow, no credible pipeline, and rising dilution risk
Executive Summary
Capricor Therapeutics (CAPR) stands as a classic example of a small-cap biotech built more on narrative momentum than operational substance. Despite years of promises around its Duchenne muscular dystrophy (DMD) treatment, the company remains unprofitable, cash-burning, and structurally dependent on future equity raises.
The FDA’s Comple…
